Biotechnology Definition | Investopedia

DEFINITION of 'Biotechnology'

The use of living organisms to make products or run processes. Biotechnology is best known for its huge role in the field of medicine, and also finds application in other areas such as food and fuel. As biotechnology involves understanding how living organisms function at the molecular level, it combines a number of disciplines biology, physics, chemistry, mathematics, science and technology. Modern biotechnology continues to make very significant contributions to extending the human lifespan and improving the quality of life through numerous ways, including providing products and therapies to combat diseases, generating higher crop yields, and using biofuels to reduce greenhouse gas emissions. The term biotechnology is believed to have been coined in 1919 by Hungarian engineer Karl Ereky. Also known as biotech.

Biotechnology in its basic form has found application for thousands of years, when humans first learnt to produce bread, beer and wine using the natural process of fermentation. For centuries, the principles of biotechnology were restricted to agriculture harvesting better crops and improving yields by using the best seeds and breeding livestock.

The field of biotechnology began to develop rapidly from the 19th century, with the discovery of microorganisms, Mendels study of genetics, and ground-breaking work on fermentation and microbial processes by giants in the field such as Pasteur and Lister. Early 20th century biotechnology led to the major discovery by Alexander Fleming of penicillin, large-scale production of which was achieved in the 1940s.

Biotechnology took off from the 1950s, spurred by a better understanding in the post-war period of cell function and molecular biology. Every decade since then has produced major breakthroughs in biotechnology. These include the discovery of the 3D structure of DNA in the '50s; insulin synthesis and the development of vaccines for measles, mumps and rubella in the '60s; massive strides in DNA research in the '70s; the development of the first biotech-derived drugs and vaccines to treat diseases such as cancer and hepatitis B in the '80s; the identification of numerous genes and the introduction of new treatments in decades for managing multiple sclerosis and cystic fibrosis in the '90s; and the completion of the human genome sequence in the '90s, which made it possible for scientists worldwide to research new treatments for diseases with genetic origins like cancer, heart disease, and Alzheimers.

The biotechnology sector has grown by leaps and bounds since the 1990s. The industry has spawned giant companies in the medical space such as Gilead Sciences, Amgen, Biogen Idec and Celgene. At the other extreme are thousands of small, dynamic biotech companies, many of which are engaged in various aspects of the medical industry such as drug development, genomics, or proteomics, while others are involved in areas like bioremediation, biofuels and food products.

Read the original post:
Biotechnology Definition | Investopedia

How biotechnology can optimize agriculture in Nigeria – Vanguard … – Vanguard

By Abdallah el-Kurebe

With the down turn in the global prices of oil, we now have to prospect our solid minerals. We have to return to agriculture, President Buhari to members of the Council of Saudi Arabian Chambers of Commerce and Industry.

According to the United Nations projections, the world population will be 9.8 billion people by 2050 and Nigeria which currently ranks seventh, will become the third most populous, replacing United States. It is currently about 200 million people.HARVEST: Women with baskets of tomatoes harvested from farmlands provided under the Restoring Agricultural Assets of IDPs, Returnees and Vulnerable Host Families in NorthEast Nigeria project, put together by the Food and Agriculture Organisation of the United Nations; the UN Central Emergency Response Fund and the governments of Ireland, Japan and Belgium.

Since his assumption of office in May 2015, President Muhammadu Buhari has repeated said that the nations economy must be diversified to, especially Agriculture which must cease from being treated as development programme but be treated as business. Our goal will be to pursue government supported private sector agriculture value chain to make agriculture more productive, efficient and competitive.

The drastic fall of oil prices in the international market has directed the thinking of the Buhari administration to diversify the economy to, specifically agriculture and one possible means of doing this is the deployment of biotechnology.

It serves as a tool for sustainable development in agriculture and could boost food security in Nigeria. It is therefore appropriate for the country in order to boost the production of maize, cotton, rice, beans, wheat, cassava, etc to, not only meet up with our consumption needs but also for the purpose of commercialization.

Dr. Muhammad Lawan Umar, a plant breeder with Institute for Agricultural Research of Usmanu Danfodiyo University, Zaria observes that Biotechnology has made possible what was impossible for the traditional methods to make by use of the new techniques. This has become realisable, especially I advanced countries, where such technology has been adopted and it can work wonders for developing countries, like Nigeria.

He gives an example of the pod-borer resistant beans on which efforts had been made to discover the source of the resistance without success. So far, 15,000 different types of varieties have been assembled and screened in order to identify the cause of the resistance. Experts agreed that the only option is to use biotechnology, which has now identified the maruca-resistant beans. This was a global phenomenon from America down to Africa where the problem of maruca is more, he said.

Umar adds that tests have been conducted in West Africa (Ghana, Nigeria and Burkina Faso) where traits that were resistant to those insects have been identified.

Biotechnology been used to transfer the genes to farmer-specified varieties adapted to different ecology in these West African countries. We have realised four to five times increase in yields and we are moving towards commercialisation.

Secondly, biotechnology has shortened the time of developing and releasing a variety. This is done in three to four years if there are no regulatory agencies that may delay the process. With the use of molecular marker, you can select a plant at a tender stage in fact you can select a grain to see which one carries the gene or not. But with the conventional methods, we used to spend eight to nine years to develop and release a variety because we had to plant it, grow it and then harvest it before you can assess, he explained.

Adebayo Olusoji, an Agriculture Extension and Rural Development Expert with the Oyo State College of Agriculture and Technology, Igboora said that biotechnology is an innovation has done well for Nigerias cassava production. Presently, we have more than twenty genetically modified improved cassava varieties with an average yield of 25-45 tonnes per hectare.

He adds that in cassava value chain, processing of improved cassava has resulted in high quality starch, which is being exported abroad. Biotechnology has not left out annual crops like maize, soybean, etc. As we have pro-vitamin A maize, Alfa toxin free soybean, etc.

A good step is Nigerias adoption of biotechnology in agriculture through the Biotechnology Policy, which led the establishment of the National Biotechnology Development Agency (NABDA). And in order to address safety concerns, the National Bio-safety Management Agency (NBMA), a full-fledged agency that provides regulatory frameworks for sustainability has been established.

Prof. Lauwali Abubakar, the Director at the Centre for Agricultural and Pastoral Research of the Usmanu Danfodiyo University, Sokoto said that Nigerias population growth was against the low agricultural productivity. Our population is expanding while our agricultural production is low. We need biotechnology, which will bring multiple food production in a limited period.

Hamma Ali Kwajaffa is former President of the National Cotton Association of Nigeria (NACOTAN) and Director General at Nigerian Textile Manufacturers Association said that biotechnology could develop African cotton, especially now that the product is in completion in the international market.

Biotechnology has increased the tonnage of cotton per hectare in America, China and India and their farmers are happy with it. We have not been able to achieve one tonne per hectare in Nigeria while those using biotechnology are harvesting five tonnes per hectare. Generally, our farmers have been left out, he said.

He cited Burkina Faso as the number country in Africa that applied biotechnology on commercial level for cotton. When Nigeria starts full application of biotechnology after field trials, the story will be a different one. Biotechnology will boost our agricultural productivity in no small measure.

Thanks to biotechnology, India which was least known in agriculture became worlds largest producer of cotton; Argentina leads in the production and export of soybeans and Burkina Faso, in the last two years became Africas largest producer of BT cotton.

Therefore, Nigeria has no choice than to consider the deployment of agricultural biotechnology, especially if food insecurity is our concern against the projected population explosion.

Read more here:
How biotechnology can optimize agriculture in Nigeria - Vanguard ... - Vanguard

Shareholders Group of Nerium Biotechnology, Inc. announces important reminder to vote for much needed change to … – PR Newswire (press release)

"Dear Fellow Nerium Shareholders,

We are at a critical juncture for the shareholders of Nerium Biotechnology, Inc. ("Nerium" or the "Company"). Failure to take action and vote for change will have significant consequences.

Your vote will impact the future of the Company and you have the opportunity to effect positive change by voting FOR the nominees proposed by the Shareholders Group.

A more detailed version of this letter is available on our website at: http://www.nbishareholders.com

The Shareholders Group has proposed six new highly qualified directors to be elected at the Company's upcoming Annual General Meeting of Nerium shareholders to be held on June 29, 2017. Shareholders can support change by voting their YELLOW form of proxy (the "YELLOW Proxy") in support of the directors proposed by the Shareholders Group (the "Shareholders' Nominees").

Critical Reasons to Replace Current Board and Management:

The decision to replace the current Board and Management is never easy, especially for those of you who have long-term personal relationships with some of the individuals involved. However, there comes a time when personal feelings must be set aside and action must be taken. In our opinion, the time has come for a change to the manner in which the Company is managed and operated. The case for taking action is compelling and has only become more so over the course of the last several weeks.

You have likely received the Shareholders Group's Proxy Circular (the "Shareholders Group Circular") and Yellow Proxy, which provides shareholders the opportunity to vote for change and a viable future for our Company. The Shareholders Group Circular, Yellow Proxy, and letter to shareholders can also be found on our website at http://www.nbishareholders.com. We have laid out, in detail, the many reasons why the current Board and Management must be replaced, as well as our plan for the Company going forward. The Shareholders Group's plan for the Company is based on a simple and much desired premise saving our Company in order to ultimately return value to shareholders.

The Shareholders Group believes that shareholders must take immediate action, or face the prospect of the Company ceasing to be a going concern in the near future.

Even prior to these new, very disturbing revelations, the Shareholders Group had clearly articulated the case for replacing the current Board and Management. It is no longer a debate it is a necessity.

The current Board and Management have had ten years to do right by shareholders. It is time for a change the very future of our investment depends on it.

The Shareholders' Nominees pledge to ensure that the Company is operated in a transparent manner, conducts good corporate governance, communicates regularly with shareholders, and discloses all important decisions, transactions or events.

In conclusion, the Shareholders Group believes that replacing the Board is critical to stabilize Nerium. The time is NOW, to effect positive change. Vote to save our Company by submitting your YELLOW Proxy in favor of the Shareholders' Nominees.

Sincerely Yours,

/s/ Brad BuscherBrad Buscher

On behalf of the Nerium Biotechnology, Inc. Shareholders Group

Your vote is extremely important. Every vote counts to save the Company.

Time is of the essence. Vote via email or fax to ensure your vote is received in a timely manner."

The above letter has also been mailed to Nerium shareholders and a more detailed letter, along with materials relating to the meeting, can be found on the Shareholders Group's website at http://www.nbishareholders.com

Time is Limited. You are encouraged to submit your YELLOW Proxy by EMAIL OR FAX in advance of the deadline at 8:00 a.m. (Eastern Time) on June 27, 2017

DO NOT use the proxy provided by Management. Shareholders are urged to discard that proxy and follow the instructions on the YELLOW Proxy. If you have already voted using Management's proxy form but wish to support the Shareholders Group, simply vote using the YELLOW Proxy. A later dated YELLOW Proxy will supersede a previously submitted vote.

Shareholders who require assistance with voting or have questions should immediately contact Laurel Hill Advisory Group at 1-877-452-7184 toll-free (416-304-0211 collect), or by email at assistance@laurelhill.com.

About the Shareholders Group

The Shareholders Group is comprised of a number of shareholders of Nerium Biotechnology, Inc. who collectively own or control more than 2.3 million shares of the Company's common stock. The Shareholders Group was formed in June of 2016 for the sole purpose of removing the Company's current management team and replacing them with individuals who will act in accordance with their fiduciary duty to the Company and its shareholders.

Further Information or Assistance

For more information or if you require assistance with voting, please contact the proxy solicitation agent for the Shareholders Group:

Laurel Hill Advisory GroupNorth America Toll Free: 1-877-452-7184Collect Calls Outside North America: 1-416-304-0211 Email: assistance@laurelhill.com

SOURCE The Shareholders Group of Nerium

Read the original post:
Shareholders Group of Nerium Biotechnology, Inc. announces important reminder to vote for much needed change to ... - PR Newswire (press release)

Impossible Burger blowback: Will irrational fears of biotechnology block introduction of sustainable foods? – Genetic Literacy Project

Two entities that seem like they should be on the same page a coalition of environmental groups and a plant-based food company are at odds.

And the flash point is a veggie burger.

Impossible Foods is facing scrutiny about the safety of a key ingredient in its trademark Impossible Burger, commonly known as the veggie burger that bleeds.

The controversy arose when theNew York Timespublished an article highlightingcorrespondencebetween the FDA and Impossible Foods that environmental groups say indicates that the protein had not met the agencys approval before going to market about a year ago.

Currently our FDA, EPA and USDA regulations are falling behind the very quickly moving development of new technologies, and one of the ways that our regulatory agencies are falling behind is they are not assessing the process of genetically engineering these ingredients, said Dana Perls of Friends of the Earth, one of the groups that raised concerns about Impossible Foods safety testing.

[Read the GLPs profile on Friends of the Earth.]

[The companys CEO and founder, Patrick Brown] said the groups objections are more about the use of biotechnology than the product itself.

The vast majority of their effort is an antiscience, anti-GMO crusade, Brown said. Their strategy has tended to be to try to effectively take down any company that is using biotechnology by whatever means they can come up with.

[Editors note: Below is a letter by Impossible Burger CEO and founder Patrick Brown, republished in full with permission from the company.]

The New York Times published an Aug. 8 article falsely implying that Impossible Foods is trying to evade US Food and Drug Administration regulations and putting consumers at risk by selling a product (the Impossible Burger) containing soy leghemoglobin. The article was chock full of factual errors and misrepresentations and was instigated by an extremist anti-science group with the deliberate intention of damaging our reputation.

Heres the truth:

The greatest threat the world faces today is the enormously destructive impact that our use of animals as a food technology has on climate, water, wildlife and biodiversity, global food security and political stability. Although little known to the public and almost completely ignored by the news media, this threat is well recognized by environmental and climate scientists and organizations including the UN Environmental Program, the UN Food and Agriculture Organization, and the Union of Concerned Scientists, among many others. The problem is not going to be solved by asking that people give up, or even reduce, consumption of the animal-derived foods they love; the demand for meat, fish and dairy foods is growing even faster than the human population. Nothing is more important to the planet our children and future generations will inherit, or their quality of life, than finding a solution to this dilemma.

Thats why I founded Impossible Foods. Our singular mission is to enable the world to continue to enjoy the foods they love and increasingly demand, without catastrophic damage to the environment. Our strategy was simple: invent a better way to transform plants into delicious, nutritious, safe and affordable meat, fish and dairy foods that consumers love. Then let consumers choose. If we do our job right, the market will take care of the rest. Commitment to the health, nutrition and safety of our customers is an inseparable part of our mission; its at the heart of why we exist, embedded in our ethos and everything we do.

With support from investors who understand and believe in our mission, we built a team of scientists who have worked tirelessly on this problem, understanding meat what underlies its flavor, texture and all its physical properties far better than it was ever understood. One of many discoveries they made, perhaps the most important, is that a molecule called heme is what makes meat taste like meat. Without heme, you cant make meat that will satisfy the billions of people who love meat.

Heme is an iron-containing molecule thats essential for life on Earth. Its found in every living organism. Its the magic molecule that enables the cells in our bodies and in every living being on Earth to benefit from the oxygen in our atmosphere. Its the molecule that carries oxygen in our blood, makes our blood red and our lips pink. Because its in every plant and animal, humans have been eating heme every day since the first human walked on Earth. The reason that animal tissues (meat) tastes like meat and unlike any vegetable, is that animal tissues contain hundreds to thousands-fold more heme than plant tissues.

To accomplish our essential mission, we needed to find a safe way to produce heme without using animals. We used yeast cells, into which we introduced a plant gene encoding a protein called soy leghemoglobin thats naturally found in the roots of soy plants. The heme in the Impossible Burger is atom-for-atom identical to the heme found in meat, fish, plants and other foods. Soy leghemoglobin carries the heme molecule in the same way a very similar protein, myoglobin, carries heme in muscle tissue (meat). Myoglobin is just one of the thousands of different heme proteins we all consume safely in our diets every day.

The health and safety of our customers is our first priority. The foods in our diet and the molecules and ingredients they contain are by default presumed to be safe, but only a minuscule fraction have ever been scientifically tested for their safety. Although there was never a reason to suspect that soy leghemoglobin would pose any more risk than myoglobin, or any of the new proteins we encounter in our diet all the time, we started four years ago to do a deep scientific study of its safety, including any potential for toxicity or allergenicity. The data we collected and our analyses were documented and reviewed by three independent food-safety experts in toxicology, allergenicity and yeast. In 2014, this expert panel unanimously concluded based on all the evidence that the protein is generally recognized as safe (GRAS) for human consumption. This is the approach followed by thousands of food companies to meet the FDA requirement that foods be generally recognized as safe. But we did more.

There is no legal or regulatory requirement that a companys finding of GRAS be submitted to the FDA for review. And its frequently not done. In fact, a total of only 709 have been submitted since the GRAS Notification system was put in place almost 20 years ago in 1998. But we did it because we recognize and respect the value of the FDA as guardian of the safety of the American food supply, one of the safest in the world.

We wanted the FDA to review our GRAS determination, to have the added benefit of their expertise, and to assure consumers that our testing of leghemoglobin has passed the most rigorous scrutiny. After submitting our GRAS determination, the FDA reviewed it, and had some questions. To address them, we conducted additional tests. And the tests turned out just as we expected: no adverse effects in rats consuming leghemoglobin every day for a month at levels more than 200 times what an average American would consume if all the ground beef in their diet were the Impossible Burger, and very low risk of allergenicity. A panel of the worlds leading experts in food safety and allergenicity has reviewed the new data, as well as the data originally submitted.

The expert panel has again unanimously concluded that soy leghemoglobin is safe; it is GRAS.

Impossible Foods has always worked constructively with the FDA, whose role as guardian of food safety for the nation we deeply respect. We will be submitting the additional data, along with the expert panels analysis of it, to the FDA this month. And FDA will make Impossible Foodss submission hundreds of pages of safety and allergenicity test results and the expert analysis of those results publicly available on its web site soon thereafter. In addition, in an abundance of caution, we clearly label our product as containing potential allergens: wheat and soy also in compliance with federal regulations. Finally, restaurants where the Impossible Burger is sold also comply with federal regulations about labeling.

Impossible Foods is proud of the safety of its first product, the Impossible Burger, and is committed to the health and safety of our customers. Thats why weve gone far beyond merely complying with food safety regulations, and we always will. I am confident in saying that the Impossible Burger is the safest and most thoroughly safety-tested burger in history. In striking contrast, the alternative, animal-derived burger is one of the least safe and most inadequately tested foods on the market.

And were committed to solving the most urgent threat the world faces today: the use of animals in the food system. Since the small-scale launch of the Impossible Burger, with just 50,000 lbs sold to date (10 billion lbs of ground beef were sold in the same time period), and working with our great restaurant partners, the Impossible Burger has already had an outsized impact: weve had an overwhelmingly positive response from consumers, and weve reduced greenhouse gases emissions by the equivalent of removing 246 American cars from the road for a year, reduced the land footprint of meat production by an area half the size of New Yorks Central Park, saved as much fresh water as 50,000 average Americans drink in a year, and saved more than 100 cows from slaughter. We cant solve this problem unless people love our burger.

Impossible Foods intends to be the most open and transparent company in the world. We welcome every opportunity to answer questions from the public and media, and share our answers on our social media channels. Before deciding how you feel about Impossible Foods or the Impossible Burger, read our story and then decide for yourself.

The rest is here:
Impossible Burger blowback: Will irrational fears of biotechnology block introduction of sustainable foods? - Genetic Literacy Project

Trumann student starting ABI biotechnology research internship – Democrat Tribune

Dustin Rhoads of Trumann is participating in Biotechnology Research Internship at Arkansas Biosciences Institute. (Photo provided)

Five Arkansas State University students are pursuing their interest in science this summer through the Biotechnology Research Internship Program at the Arkansas Biosciences Institute (ABI) facility on campus. One of those students, Dustin Rhoads, is from Trumann.

The program provides basic support for A-State undergraduate science majors who want research experience in life sciences or applications of life sciences during the summer of their sophomore or junior years.

Each student is matched with a faculty mentor who is conducting research related to biotechnology or biology from one of several departments and colleges, based largely on the student's interests. Selection also is based on academic credentials.

The students, along with their future plans and comments from their applications are:

Dustin Rhoads plans to go to dental school after completing his degree at A-State. His faculty mentor also is Dr. Malathi Srivatsan.

"I chose to apply for this internship mostly because of my interest in the field," Rhoads said. "Neurology has always been and interest of mine. Furthermore, the research we are doing at Dr. Srivatsan's Lab could be used to help so many people. Neuroregeneration could impact the lives of millions, and to be a part of something that could do that is very special to me. What sparked my interest in science was the way it's completely unique from all other academic fields, it has no sense of complacency, and is forever evolving. Im the kind of person who would rather study how things work as opposed to memorizing hard set facts, so the sciences are definitely for me regarding that aspect. I chose Arkansas State University because growing up I was always around it, almost developing it as a second home before even leaving high school, also accompanied with the report of its programs, made it a complete match for me."

The other students are Madalyn Rose Weiner of Little Rock, Oliver Dozier of Paragould, Kayleigh Nelson of Marion, and Aylin Villalpa-Arroyo of Hidalgo, Mexico.

Each internship is valued at $2,500. The students work 20 hours per week for 10 weeks. An additional $500 is provided to the supporting laboratory for research supplies.

Read more:
Trumann student starting ABI biotechnology research internship - Democrat Tribune

Puma Biotechnology Inc (PBYI) Receives Buy Rating from Citigroup Inc. – The Cerbat Gem


Stock Observer
Puma Biotechnology Inc (PBYI) Receives Buy Rating from Citigroup Inc.
The Cerbat Gem
Puma Biotechnology logo Puma Biotechnology Inc (NYSE:PBYI)'s stock had its buy rating reissued by investment analysts at Citigroup Inc. in a research report issued to clients and investors on Monday, May 22nd, MarketBeat Ratings reports. They ...
Puma Biotechnology Inc - Receive News & Ratings DailyBBNS
The Puma Biotechnology Inc (PBYI) Major Shareholder Adage Capital Partners Gp, LL Sells 247260 Shares of StockBangaloreWeekly
Puma Biotechnology Target of Unusually Large Options Trading ...Sports Perspectives
Transcript Daily -Markets Daily -Stock Observer
all 60 news articles »

The rest is here:
Puma Biotechnology Inc (PBYI) Receives Buy Rating from Citigroup Inc. - The Cerbat Gem

$10M for birthplace of biotechnology – Innovators Magazine

(CALIFORNIA)

Thebirthplace of biotechnology is to receive$10 million for a pioneering precision medicine programme.

It was announced this week thatthe California Initiative to Advance Precision Medicine (CIAPM) has been awarded the money from the local governments budget, a decision welcomed by theCalifornia Life Sciences Association (CLSA).

Sara Radcliffe, President & CEO, CLSA, said:California Life Sciences Association (CLSA) applauds Governor Jerry Brown, California State Senate and California Assembly leaders for their strong support of life sciences innovation, as demonstrated again in this years 2017-2018 budget deal which allocates a $10 million investment in precision medicine research. California is the birthplace of biotechnology and today the states life sciences sector employs over 287,200 people working to develop innovative new medicines, technologies and therapies needed to treat and cure patients.

The Californian city of San Diego ishostingtheBIO International Conventionalthe global event for biotechnology next week. It will celebrate the industrys many breakthroughs and on going impact on society.It will take place at the San Diego Convention Center between 19 and 22 June.

BIO International ConventionalCalifornia Initiative to Advance Precision Medicine

Original post:
$10M for birthplace of biotechnology - Innovators Magazine

FBI says Chinese spying, theft of US agricultural biotechnology is ‘a growing threat’ – Genetic Literacy Project

As a group of visiting scientists prepared to board a plane in Hawaii that would take them back home to China, U.S. customs agents found rice seeds in their luggage. Those seeds are likely to land at least one scientist in federal prison.

Agriculture today is a high-tech business, but as that technology has developed, so has the temptation to take shortcuts and steal trade secrets that could unlock huge profits. The FBI calls agricultural economic espionage a growing threat and some are worried that biotech piracy can spell big trouble for a dynamic and growing U.S. industry.

Had they succeeded in stealing the gene-spliced rice, the scientists may have been able to reverse-engineer it and ultimately undercut [US company] Ventrias market. [Ventria President and CEO Scott] Deeter says it could have driven his company out of business.

Where the commodity in question is grown in open fields, its sometimes difficult, [Jason] Griess [the assistant U.S. attorney for the Southern District of Iowa] says.

Theft of intellectual property costs the U.S. economy hundreds of billions of dollars each year, according to a recent report from the Commission on the Theft of American Intellectual Property, a Washington, D.C.-based ad-hoc panel formed to study intellectual property theft. China, the authors say, is the biggest offender.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Spies In The Field: As Farming Goes High-Tech, Espionage Threat Grows

View original post here:
FBI says Chinese spying, theft of US agricultural biotechnology is 'a growing threat' - Genetic Literacy Project

ASA Provides Input to USDA, FDA on Advances in Biotechnology – KTIC

The American Soybean Association (ASA) submitted comments this week to both the U.S. Department of Agriculture (USDA) and the U.S. Food and Drug Administration (FDA) regarding regulations in response to advances in genetic engineering.

ASA included in comments to USDA, that biotechnology is an essential tool in farmers quest to produce enough food to meet the needs of 9.7 billion people by 2050, creating the need for a clear, science-based regulatory system in the U.S. as an example and standard for regulatory systems of biotechnology internationally.

While applauding USDAs efforts to reduce the burden on regulated entities, ASA expressed concern that aspects of the rule as proposed will increase the regulatory burden and stifle research and innovation.

Additionally, ASAs comments to FDA cheered USDAs proposal to exclude certain genome-editing techniques from requiring pre-market approvals because they are low risk and could be found in nature or achieved through traditional breeding methods.

ASA concluded its support saying, Technological advancements such as genome editing offer an additional tool to combat threats while also improving sustainability in production agriculture.

Full comments to USDA and FDA can be found here and here, respectively.

Excerpt from:
ASA Provides Input to USDA, FDA on Advances in Biotechnology - KTIC

This Biotechnology Company Wants to Reanimate the Brain-Dead – TrendinTech

Ira Pastor, CEO of Bioquark, a Philadelphia-based biotechnology company, believes we will on day be able to reset the brain of patients declared brain-dead using a series of stem cell injections and nerve stimulations.

Until recently, death was medically defined as a loss of heart and lung function but as medical technology has advanced so has the qualifications. Now, since both heartbeat and breathing functions can be performed for a patient by machine, death is almost universally declared when there is a loss of activity in the brain stem. However, Pastor does think that this loss of brain function is as irreversible as weve come expect.

Initially, Bioquark was slated to start trials for the procedure last year in India but, due to strong opposition by the Indian Council of Medical Research, those studies were canceled. Nevertheless, Ira Pastor and his collaborator Himanshu Bansal, an orthopedic surgeon, remain undaunted and have announced a new series of test to happen soon in a nameless South American country.

Although they have not released the details of the revolutionary procedure, we can gather a general idea of their plan to reanimate the brain-dead from the papers regarding their original canceled trial.

Originally, the researchers wanted brain-dead subjects between the ages of 12 and 65. Ideally, the cause of the brain damage would be due to traumatic injury. Scientists would look at MRIs to determine eligibility, then brain cells would be harvested from the patients blood. After the stem cells are injected, the patients would get another injection, this time peptides, directly to the spinal column. The series of injections is followed by two weeks of nerve stimulation, specifically the median nerve, by lasers, which Bioquark thinks is the key to reversing brain death.

Bioquark has not clarified how it intends to obtain consent from technically dead patients but in spite of the controversy, this study is not alone. The work at Bioquark is part of a larger program concerning neuro-reanimation and regeneration called ReAnima.

Pastor, who also serves on the advisory board for the project, told the Daily Mail: The mission of the ReAnima Project is to focus on clinical research in the state of brain death, or irreversible coma, in subjects who have recently met the Uniform Determination of Death Act criteria, but who are still on cardio-pulmonary or trophic support a classification in many countries around the world known as a living cadaver.

More News to Read

comments

Read more from the original source:
This Biotechnology Company Wants to Reanimate the Brain-Dead - TrendinTech

Biotechnology company opens mosquito factory in Lexington – Lexington Herald Leader


Lexington Herald Leader
Biotechnology company opens mosquito factory in Lexington
Lexington Herald Leader
A Lexington biotechnology company aimed at fighting mosquito-borne diseases such as the Zika virus opened a mosquito factory Friday on Malabu Drive. MosquitoMate, a biotechnology company founded by University of Kentucky entomology professor ...

and more »

Go here to see the original:
Biotechnology company opens mosquito factory in Lexington - Lexington Herald Leader

Biotechnology expert proposed for top Chinese University of Hong Kong post – South China Morning Post

An internationally renowned biotechnology scientist, Professor Rocky Tuan Sung-chi, has been recommended to succeed Joseph Sung Jao-yiu as Chinese University vice-chancellor.

Born in Hong Kong and educated in the United States, Tuan is currently working at the University of Pittsburgh as director of the institutions cellular and molecular engineering lab, executive vice-chairman of the Department of Orthopaedic Surgery and a professor in the Department of Bioengineering.

He has been serving as a distinguished visiting professor and director of the Institute for Tissue Engineering and Regenerative Medicine at Chinese University.

The institutions council said on Thursday that it would recommend Tuan to be the next vice-chancellor. It will hold a consultation of up to six weeks with staff, students and alumni, but the universitys teachers association vowed to boycott it, saying the council had fooled it by saying it was not sure who the candidate was.

In May 2016, Tuan was one of the 10 Carnegie Science Award winners for his extensive experience in applying adult stem cells for tissue engineering and regenerative medicine.

Hes a good scientist, professionally speaking, with a major interest in bone and tendon regeneration, Professor Chan Wai-yee of the universitys School of Biomedical Sciences said. He used to chair the biology and medicine panel of the Research Grants Council so he should know better than others what improvements can be made to develop Hong Kongs scientific research.

I have high expectations of him. As a successful scholar who has worked for the Research Grants Council for so many years, he could at least reflect our wish for more funding and resources.

However, Professor Chan King-ming, president of the Chinese University Teachers Association, said he was angry about the announcement and that staff and students were being played by the universitys top administration, who two weeks ago told the association they were still not sure about the candidate.

Chan King-ming also said Tuan lacked outstanding academic status and administrative experience. Seldom were his papers published by top journals and he has never served at the level of deputy vice-chancellor or dean in any university, the biochemistry scholar said.

Read this article:
Biotechnology expert proposed for top Chinese University of Hong Kong post - South China Morning Post

Nerium Biotechnology Issues Shareholder Letter and Commences Selling NeriumAD Advanced in Mexico – Marketwired (press release)

SAN ANTONIO, TEXAS--(Marketwired - June 15, 2017) - Nerium Biotechnology, Inc. ("Nerium" or the "Company") today announces that it is mailing a letter to shareholders in advance of the Company's annual meeting on June 29, 2017. The shareholder letter which is reproduced below, provides important information for shareholder consideration regarding the election of directors at the annual meeting. This is an important meeting for shareholders as the decisions made with respect to the election of the Company's board of directors will determine Nerium's future.

Nerium is pleased to confirm the support of its largest shareholders for the re-election of the current board of directors (the "Board"). The shareholder letter, as well as a letter received by Nerium from Crandell Addington, a large shareholder of Nerium and CEO, Chairman and Director of Phoenix Biotechnology, will be mailed to shareholders today. A copy of the shareholder letter and other materials is available on the Company's issuer profile on SEDAR and on the Company's website http://www.nbiinvestors.com.

Your Board needs your support, please vote using only the GREEN proxy FOR Dennis R. Knocke, Gustavo A. Ulloa, Jr., Richard J.G. Boxer, Michael Burke, Kerry Mitchell and Peter A. Leininger, M.D.

Shareholders are encouraged to vote via the internet at http://www.voteproxyonline.com and enter the 12 digit control number located on your GREEN proxy, to ensure your vote is received in advance of the proxy deadline of June 27, 2017 10:00 a.m. (Toronto time). Shareholders may also vote by sending their signed GREEN proxy to TSX Trust Company via fax: 416-595-9593 or email: tmxeproxysupport@tmx.com or by mail in the envelope provided.

The Company also announces that it has commenced selling its over-the-counter product, NeriumAD Advanced, in Mexico. This represents the effective development of a new distribution channel for the Company's products and a source of future revenue that does not depend upon the cooperation of the Company's distributor, Nerium International LLC (the "Distributor").

It has come to the Company's attention that the amount of the Distributor's sales in 2015 and 2016 were incorrect in the Company's June 2, 2017 management information circular (the "Circular"). The Company received multiple versions of the Distributor's 2015 financial statements, each containing different numbers. The Company mistakenly included as the amount of the Distributor's 2015 sales an amount provided in an earlier version of the Distributor's 2015 financial statements and included the amount from a later version of the Distributor's 2015 financial statements as the 2016 sales amount. In fact, the Distributor's 2015 sales were US$496,838,912. The Company has never received a final version of the Distributor's financial statements for 2016, but based on a draft version of the Distributor's 2016 financial statement, the Distributor's 2016 sales were US$336,331,483. Corrected versions of the tables included on pages 19 and 20 of the Circular are provided below. The Company does not believe the updated information changes in any material respect the issues raised by it in the Circular.

Year

In response to the group of dissident shareholders retaining a proxy solicitation agent in connection with the Company's upcoming annual meeting, the Company has retained Shorecrest Group to act as proxy solicitation agent on behalf of the Company for a fee of approximately US$75,000 and reimbursement of its reasonable out-of-pocket expenses. All costs of solicitation by management will be borne by the Company.

YOUR VOTE IS IMPORTANT. To support your current Board, please vote using only your GREEN proxy. Please disregard any other proxy received. If you have already voted using the dissident proxy and wish to vote FOR the current directors, please vote using the GREEN proxy sent to you. This will automatically revoke any previous proxies submitted. If you have any questions or require assistance in voting, please contact the proxy solicitation agent Shorecrest Group toll free at 1-888-637-5789 or direct 647-931-7454.

About Nerium Biotechnology, Inc.

Nerium Biotechnology, Inc. is a biotechnology company involved in the research, product development, manufacture and marketing of Nerium oleander-based products. The Company's shares are not listed on any stock exchange or quotation system.

Forward Looking Statements: Statements made in this press release that relate to future plans, expectations, events or performances, including with respect to the future distribution and sales of the Company's products and possible revenue, are forward looking statements. Forward-looking statements are not based on historic facts, but rather on current expectations regarding future events. They are based on information available to management and/or assumptions management believes are reasonable. Many factors could cause future events and outcomes to differ materially from those discussed in the forward-looking statements. Although the forward-looking statements are based on what management believes are reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with these forward-looking statements. The forward-looking statements in this press release are made as of the date hereof and, except as required by applicable securities laws, the Company does not assume any obligation to update or revise such forward-looking statements. More information about the Company is available in its disclosure documents, all of which are available on the Company's issuer profile on SEDAR at http://www.sedar.com

To view the shareholder letter and the letter received by Nerium from Crandell Addington please click the following link: http://media3.marketwire.com/docs/NeriumLetter.pdf

Link:
Nerium Biotechnology Issues Shareholder Letter and Commences Selling NeriumAD Advanced in Mexico - Marketwired (press release)

Returning to Growth and Value Creating:: Vir Biotechnology, Inc., (NASDAQ: VIR) – NasdaqNewsFeed

EPS growth is an important number as it gives a suggestion of the future prospects of a company. It is usually expressed as a percentage and is then referred to as the EPS growth rate. Growth in EPS is an important measure of administration performance because it shows how much money the company is making for its investors or shareholders, not only because of changes in profit, but also after all the effects of issuance of new shares (this is especially important when the growth comes as a result of acquisition).

Vir Biotechnology, Inc., belongs to Healthcare sector and Biotechnology industry. The companys Market capitalization is $2.42B with the total Outstanding Shares of 261. On 27-01-2020 (Monday), VIR stock construct a change of 24.19 in a total of its share price and finished its trading at 24.77.

Profitability Ratios (ROE, ROA, ROI):

Looking into the profitability ratios of VIR stock, an investor will find its ROE, ROA, ROI standing at 0%, 0% and 66%, respectively. Return on assets (ROA) is a financial ratio that shows the percentage of profit a company earns about its overall resources. A performance measure used to estimate the efficiency of an investment or to compare the ability of some different investments. ROI measures the amount of return on an investment relative to the investments cost.

Earnings per Share Details of Vir Biotechnology, Inc.:

The EPS of VIR is strolling at -1.26, measuring its EPS growth this year at -567.7%. As a result, the company has an EPS growth of 19.9% for the approaching year.

Given the significance of identifying companies that will make sure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years.

We cant have sufficient maintenance the once will always replicate the difficult, but logically stocks that have grown earnings per allowance strongly in the subsequent to are a fine bet to keep on to take effect as a result.

Analysts mean target price for the company is $26 while analysts mean suggestion is 2.2.

A beta factor is used to measure the volatility of the stock. The stock remained 12.16% volatile for the week and 7.74% for the month.

Historical Performance In The News:

Taking a look at the performance of Vir Biotechnology, Inc. stock, an investor will come to know that the weekly performance for this stock is valued at 51.25%, resulting in a performance for the month at 96.32%.

Therefore, the stated figure displays a quarterly performance of 73.25%, bringing six-month performance to 0% and year to date performance of 97.02%.

P/S, P/E, P/C and P/B/ SMA50, SMA 200:

The price-to-sales is a valuation ratio that relates a companys stock price to its revenues. The price-to-sales ratio is a symbol of the value placed on each dollar of a companys sales or taxes. As of now, VIR has a P/S, P/E and P/B values of 236.77, 0 and 0 respectively. P/E and P/B ratios both are used on a regular basis by the investor to measure the value of the company and to get the right amount of the share.

Its P/Cash valued at 7.54. The price-to-cash-flow ratio is a stock valuation indicator that measures the value of a stocks price to its cash flow per share

What do you mean by simple moving average (SMA)?

A simple moving average (SMA) is an arithmetic moving average calculated by adding the closing price of the security for some time periods and then dividing this total by the number of time periods. Its distance from 20-days simple moving average is 75.25%, and its distance from 50 days simple moving average is 86.31% while it has a distance of 81.43% from the 200 days simple moving average. The companys distance from 52-week high price is 261% and while the current price is 261% from 52-week low price.

See the article here:
Returning to Growth and Value Creating:: Vir Biotechnology, Inc., (NASDAQ: VIR) - NasdaqNewsFeed

Is MacroGenics Inc (MGNX) Stock Near the Top or Bottom of the Biotechnology Industry? – InvestorsObserver

The 38 rating InvestorsObserver gives to MacroGenics Inc (MGNX) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 30 percent of stocks in the Biotechnology industry, MGNXs 38 overall rating means the stock scores better than 38 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

MacroGenics Inc (MGNX) stock is trading at $12.08 as of 11:26 AM on Wednesday, Feb 26, a gain of $1.09, or 9.87% from the previous closing price of $10.99. The stock has traded between $10.80 and $12.09 so far today. Volume today is less active than usual. So far 224,139 shares have traded compared to average volume of 358,693 shares.

To see InvestorsObserver's Sentiment Score for MacroGenics Inc click here.

View post:
Is MacroGenics Inc (MGNX) Stock Near the Top or Bottom of the Biotechnology Industry? - InvestorsObserver

Companies Like Vir Biotechnology (NASDAQ:VIR) Are In A Position To Invest In Growth – Simply Wall St

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

Given this risk, we thought wed take a look at whether Vir Biotechnology (NASDAQ:VIR) shareholders should be worried about its cash burn. In this report, we will consider the companys annual negative free cash flow, henceforth referring to it as the cash burn. Well start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

See our latest analysis for Vir Biotechnology

A companys cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at September 2019, Vir Biotechnology had cash of US$320m and no debt. Importantly, its cash burn was US$130m over the trailing twelve months. That means it had a cash runway of about 2.5 years as of September 2019. Thats decent, giving the company a couple years to develop its business. You can see how its cash balance has changed over time in the image below.

Some investors might find it troubling that Vir Biotechnology is actually increasing its cash burn, which is up 39% in the last year. And we must say we find it concerning that operating revenue dropped 4.0% over the same period. Taken together, we think these growth metrics are a little worrying. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

Even though it seems like Vir Biotechnology is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash to fund growth. By comparing a companys annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Since it has a market capitalisation of US$1.6b, Vir Biotechnologys US$130m in cash burn equates to about 8.2% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another years growth by issuing some new shares to investors, or even by taking out a loan.

Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought Vir Biotechnologys cash runway was relatively promising. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, were not too worried about its rate of cash burn. While we always like to monitor cash burn for early stage companies, qualitative factors such as the CEO pay can also shed light on the situation. Click here to see free what the Vir Biotechnology CEO is paid..

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read the original here:
Companies Like Vir Biotechnology (NASDAQ:VIR) Are In A Position To Invest In Growth - Simply Wall St

Stoke Therapeutics Added to NASDAQ Biotechnology Index – Yahoo Finance

Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). This addition is effective prior to market open today.

The NASDAQ Biotechnology Index tracks the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Selected companies must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. The NASDAQ Biotechnology Index is re-ranked annually and forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares NASDAQ Biotechnology ETF. For more information about the NASDAQ Biotechnology Index visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Stoke TherapeuticsStoke Therapeutics, Inc. (Nasdaq:STOK), is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. The companys lead investigational new medicine is STK-001, a proprietary antisense oligonucleotide (ASO) that has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome, a severe and progressive genetic epilepsy. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the company on Twitter at @StokeTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191223005097/en/

Contacts

Stoke Media & Investors: Dawn KalmarVice President, Head of Corporate Affairsdkalmar@stoketherapeutics.com 781-303-8302

Read the original:
Stoke Therapeutics Added to NASDAQ Biotechnology Index - Yahoo Finance

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? – Yahoo Finance

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the Invesco Dynamic Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on 06/23/2005.

While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency.

Sector ETFs are also funds of convenience, offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 2, placing it in top 13%.

Index Details

The fund is sponsored by Invesco. It has amassed assets over $237.70 M, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. PBE seeks to match the performance of the Dynamic Biotechnology & Genome Intellidex Index before fees and expenses.

This is comprised of stocks of 30 U.S. biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.

Costs

Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same.

Annual operating expenses for this ETF are 0.57%, making it on par with most peer products in the space.

Sector Exposure and Top Holdings

Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund's holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.

This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.

Looking at individual holdings, Biogen Inc (BIIB) accounts for about 6.67% of total assets, followed by Vertex Pharmaceuticals Inc (VRTX) and Neurocrine Biosciences Inc (NBIX).

The top 10 holdings account for about 52.31% of total assets under management.

Performance and Risk

The ETF has added roughly 18.74% and it's up approximately 17.71% so far this year and in the past one year (as of 12/19/2019), respectively. PBE has traded between $43.44 and $56.26 during this last 52-week period.

The ETF has a beta of 1.45 and standard deviation of 22.56% for the trailing three-year period, making it a high risk choice in the space. With about 28 holdings, it has more concentrated exposure than peers.

Alternatives

Invesco Dynamic Biotechnology & Genome ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PBE is a reasonable option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.

SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Nasdaq Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $4.21 B in assets, iShares Nasdaq Biotechnology ETF has $7.60 B. XBI has an expense ratio of 0.35% and IBB charges 0.47%.

Bottom Line

To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportInvesco Dynamic Biotechnology & Genome ETF (PBE): ETF Research ReportsiShares Nasdaq Biotechnology ETF (IBB): ETF Research ReportsSPDR S&P Biotech ETF (XBI): ETF Research ReportsBiogen Inc. (BIIB) : Free Stock Analysis ReportVertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis ReportNeurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Read more:
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? - Yahoo Finance

Here is What Hedge Funds Think About Unity Biotechnology, Inc. (NUBX) – Yahoo Finance

It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory winners by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index returns are more affected by a few outlier stocks (i.e. the FAANG stocks dominating and driving S&P 500 Index's returns in recent years), more than 50% of the constituents of the Standard and Poors 500 Index underperform the benchmark. Hence, if you randomly pick a stock, there is more than 50% chance that you'd fail to beat the market. At the same time, the 20 most favored S&P 500 stocks by the hedge funds monitored by Insider Monkey generated an outperformance of more than 8 percentage points so far in 2019. Of course, hedge funds do make wrong bets on some occasions and these get disproportionately publicized on financial media, but piggybacking their moves can beat the broader market on average. That's why we are going to go over recent hedge fund activity in Unity Biotechnology, Inc. (NASDAQ:UBX).

Unity Biotechnology, Inc. (NASDAQ:UBX) was in 4 hedge funds' portfolios at the end of September. UBX shareholders have witnessed a decrease in hedge fund interest recently. There were 5 hedge funds in our database with UBX positions at the end of the previous quarter. Our calculations also showed that UBX isn't among the 30 most popular stocks among hedge funds (click for Q3 rankings and see the video below for Q2 rankings). Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

5 Most Popular Stocks Among Hedge Funds

Why do we pay any attention at all to hedge fund sentiment? Our research has shown that hedge funds' large-cap stock picks indeed failed to beat the market between 1999 and 2016. However, we were able to identify in advance a select group of hedge fund holdings that outperformed the Russell 2000 ETFs by 40 percentage points since May 2014 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that'll significantly underperform the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 27.8% through November 21, 2019. That's why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to.

Ken Griffin of Citadel Investment Group

We leave no stone unturned when looking for the next great investment idea. For example Discover is offering this insane cashback card, so we look into shorting the stock. One of the most bullish analysts in America just put his money where his mouth is. He says, "I'm investing more today than I did back in early 2009." So we check out his pitch. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. We even check out this option genius' weekly trade ideas. This December, we recommended Adams Energy as a one-way bet based on an under-the-radar fund manager's investor letter and the stock already gained 20 percent. Keeping this in mind let's take a gander at the latest hedge fund action surrounding Unity Biotechnology, Inc. (NASDAQ:UBX).

Story continues

At the end of the third quarter, a total of 4 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -20% from the previous quarter. The graph below displays the number of hedge funds with bullish position in UBX over the last 17 quarters. With hedge funds' positions undergoing their usual ebb and flow, there exists a few noteworthy hedge fund managers who were increasing their holdings considerably (or already accumulated large positions).

Is UBX A Good Stock To Buy?

Of the funds tracked by Insider Monkey, Citadel Investment Group, managed by Ken Griffin, holds the biggest position in Unity Biotechnology, Inc. (NASDAQ:UBX). Citadel Investment Group has a $2.3 million position in the stock, comprising less than 0.1%% of its 13F portfolio. Coming in second is Millennium Management, managed by Israel Englander, which holds a $1.3 million position; less than 0.1%% of its 13F portfolio is allocated to the stock. Other peers that are bullish consist of Oleg Nodelman's EcoR1 Capital, Paul Marshall and Ian Wace's Marshall Wace and . In terms of the portfolio weights assigned to each position EcoR1 Capital allocated the biggest weight to Unity Biotechnology, Inc. (NASDAQ:UBX), around 0.04% of its 13F portfolio. Millennium Management is also relatively very bullish on the stock, dishing out 0.0021 percent of its 13F equity portfolio to UBX.

Seeing as Unity Biotechnology, Inc. (NASDAQ:UBX) has witnessed declining sentiment from the smart money, it's safe to say that there exists a select few money managers who sold off their full holdings in the third quarter. It's worth mentioning that Michael Castor's Sio Capital dumped the largest position of the "upper crust" of funds monitored by Insider Monkey, valued at close to $1 million in stock. Mike Vranos's fund, Ellington, also dropped its stock, about $0.1 million worth. These transactions are intriguing to say the least, as total hedge fund interest was cut by 1 funds in the third quarter.

Let's now review hedge fund activity in other stocks - not necessarily in the same industry as Unity Biotechnology, Inc. (NASDAQ:UBX) but similarly valued. These stocks are Compugen Ltd. (NASDAQ:CGEN), ShotSpotter, Inc. (NASDAQ:SSTI), Tsakos Energy Navigation Ltd. (NYSE:TNP), and ADMA Biologics Inc (NASDAQ:ADMA). This group of stocks' market values resemble UBX's market value.

[table] Ticker, No of HFs with positions, Total Value of HF Positions (x1000), Change in HF Position CGEN,4,7644,-1 SSTI,6,12594,0 TNP,7,27496,1 ADMA,11,105915,1 Average,7,38412,0.25 [/table]

View table hereif you experience formatting issues.

As you can see these stocks had an average of 7 hedge funds with bullish positions and the average amount invested in these stocks was $38 million. That figure was $4 million in UBX's case. ADMA Biologics Inc (NASDAQ:ADMA) is the most popular stock in this table. On the other hand Compugen Ltd. (NASDAQ:CGEN) is the least popular one with only 4 bullish hedge fund positions. Compared to these stocks Unity Biotechnology, Inc. (NASDAQ:UBX) is even less popular than CGEN. Hedge funds clearly dropped the ball on UBX as the stock delivered strong returns, though hedge funds' consensus picks still generated respectable returns. Our calculations showed that top 20 most popular stocks among hedge funds returned 37.4% in 2019 through the end of November and outperformed the S&P 500 ETF (SPY) by 9.9 percentage points. A small number of hedge funds were also right about betting on UBX as the stock returned 26.6% during the fourth quarter (through the end of November) and outperformed the market by an even larger margin.

Disclosure: None. This article was originally published at Insider Monkey.

Related Content

Read the original here:
Here is What Hedge Funds Think About Unity Biotechnology, Inc. (NUBX) - Yahoo Finance

BioDelivery Sciences Added to NASDAQ Biotechnology Index – Yahoo Finance

RALEIGH, N.C., Dec. 19, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). BDSIs addition to the NBI will become effective prior to market open on Monday, December 23, 2019.

Companies in the NBI must meet eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria. All securities in the NBI index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, which BDSI was accepted into in October 2019.

The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). Additionally, the NBI serves as the basis for the Blackrock iShares Nasdaq Biotechnology ETF (IBB), the largest ETF that tracks this index directly. For more information about the NASDAQ Biotechnology Index, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc. (BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, opioid dependence, and opioid-induced constipation.

Cautionary Note on Forward-Looking Statements

This press release and any statements of employees, representatives, and partners of BDSI related thereto contain, or may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the BDSIs plans, objectives, projections, expectations and intentions and other statements identified by words such as projects, may, will, could, would, should, believes, expects, anticipates, estimates, intends, plans, potential or similar expressions. These statements are based upon the current beliefs and expectations of the BDSIs management and are subject to significant risks and uncertainties, including those detailed in the BDSIs filings with the Securities and Exchange Commission. Actual results may differ materially from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the BDSIs control) including those set forth in our 2018 annual report on Form 10-K filed with the US Securities and Exchange Commission and subsequent filings. BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Story continues

2019 BioDelivery Sciences International, Inc. All rights reserved.

Contact:

Tirth T. PatelDirector of Investor Relationstpatel@bdsi.com(919) 582-0294

Go here to read the rest:
BioDelivery Sciences Added to NASDAQ Biotechnology Index - Yahoo Finance